Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

B-cell Non-Hodgkin's Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Peng Liu, M.D. & Ph.D.) · liu.peng@zs-hospital.sh.cn · 0086-021-60267405

Study leads

Peng Liu, M.D. & Ph.D.
Principal Investigator
Shanghai Zhongshan Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Stanford, United States

Real-World Study of DLBCL With Different Genetic Subtypes

DLBCL - Diffuse Large B Cell Lymphoma · Lymphoma

Abroad (travel likely)Recruiting

Shanghai, China